PMID- 25527221
OWN - NLM
STAT- MEDLINE
DCOM- 20150820
LR  - 20220321
IS  - 1522-9653 (Electronic)
IS  - 1063-4584 (Linking)
VI  - 23 Suppl 1
DP  - 2015 Jan
TI  - A systematic review of the efficacy and general safety of antibodies to NGF in 
      the treatment of OA of the hip or knee.
PG  - S8-17
LID - S1063-4584(14)01295-3 [pii]
LID - 10.1016/j.joca.2014.10.003 [doi]
AB  - To evaluate the efficacy and safety of anti-NGF antibody treatment in hip and 
      knee osteoarthritis (OA), a systematic review and meta-analysis was undertaken 
      utilizing the criteria described by the Cochrane collaboration. Both published 
      and unpublished trials were identified for tanezumab, fulranumab and fasinumab in 
      hip and knee OA; sponsors were contacted to provide and confirm data. Study 
      quality was assessed by Jadad criteria; efficacy and safety data were extracted 
      independently by two individuals and meta-analyses were performed using Revman 
      5.2. 13 randomized, controlled trials were identified: 10 of tanezumab, two of 
      fulranumab and one with fasinumab. All agents demonstrated superiority in 
      efficacy compared to placebo. The highest doses in the phase II studies of 
      tanezumab had a standardized effect size for WOMAC pain of 0.73 (CI, 0.51, 0.95). 
      Subsequent phase III studies of tanezumab and phase II studies of fulranumab and 
      fasinumab reported standardized effect sizes for WOMAC pain of -0.15-0.5, with no 
      clear distinction among dose levels. Tanezumab compared to NSAIDs and opioids 
      showed greater efficacy with a standardized effect size for WOMAC pain of 0.23 
      (CI 0.17-0.29). WOMAC function and PGA results were similar to WOMAC pain. 
      Safety, determined by odds ratios of withdrawals from studies due to adverse 
      events (AEs), was better at the lower doses than higher doses and similar among 
      all agents. These results demonstrate that antibodies to NGF provide efficacy in 
      OA and that general safety at the lower doses appears similar to placebo. 
      Additional data on both efficacy and safety of these antibodies are needed to 
      define the optimal dose to maximize benefit to risk.
CI  - Copyright (c) 2014 Osteoarthritis Research Society International. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Schnitzer, T J
AU  - Schnitzer TJ
AD  - Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, 
      Chicago, IL, 60611, USA. Electronic address: tjs@northwestern.edu.
FAU - Marks, J A
AU  - Marks JA
AD  - Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, 
      Chicago, IL, 60611, USA. Electronic address: julia.marks@northwestern.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Osteoarthritis Cartilage
JT  - Osteoarthritis and cartilage
JID - 9305697
RN  - 0 (Antibodies, Monoclonal)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Humans
MH  - Nerve Growth Factor/*antagonists & inhibitors
MH  - Osteoarthritis, Hip/*drug therapy
MH  - Osteoarthritis, Knee/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antibodies to NGF
OT  - NGF
OT  - OA
OT  - Pain
EDAT- 2014/12/21 06:00
MHDA- 2015/08/21 06:00
CRDT- 2014/12/21 06:00
PHST- 2014/06/27 00:00 [received]
PHST- 2014/08/27 00:00 [revised]
PHST- 2014/10/11 00:00 [accepted]
PHST- 2014/12/21 06:00 [entrez]
PHST- 2014/12/21 06:00 [pubmed]
PHST- 2015/08/21 06:00 [medline]
AID - S1063-4584(14)01295-3 [pii]
AID - 10.1016/j.joca.2014.10.003 [doi]
PST - ppublish
SO  - Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S8-17. doi: 
      10.1016/j.joca.2014.10.003.